CURE RARE DISEASE

View full entity profile (contributions, contracts, SEC) →

Lobbying Spend

—

Filings

Firms Hired

Active Period

2022

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2022	—	6	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
RAMPY NORTHRUP LLC	—	6

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	2
SENATE	2

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	3

Bills Explicitly Cited (1)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 8295117th Congress

Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023

2022 · second_quarter · Firm: RAMPY NORTHRUP LLC

Open original LDA filing ↗

Cited source text and reported amounts

Policies related to custom therapeutics for ultra-rare diseases; FY2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.8295, Senate).

Client expense: — · Firm income: $40,000

Matched citations: H.R.8295

Source: Senate LDA

CURE RARE DISEASE — Lobbying Disclosure | Poliscope